Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects (Q38016107)

27 August 2017

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects (English)

1 reference

27 August 2017

1 reference

1 reference

1

1 reference

27 August 2017

F Berrino

2

1 reference

27 August 2017

M Gariboldi

3

1 reference

27 August 2017

C Melani

4

1 reference

27 August 2017

A Mogavero

5

1 reference

27 August 2017

T Negri

6

1 reference

27 August 2017

P Pasanisi

7

1 reference

27 August 2017

S Pilotti

8

1 reference

27 August 2017

language of work or name

English

0 references

publication date

4 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

32

1 reference

27 August 2017

12

1 reference

27 August 2017

1475-1487

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.181

27 August 2017

0 references

cites work

On the Origin of Cancer Cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Extending healthy life span--from yeast to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Energy balance and carcinogenesis: underlying pathways and targets for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Aging, adiposity, and calorie restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Caloric restriction delays disease onset and mortality in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Reducing insulin resistance with metformin: the evidence today

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Obesity and cancer risk: recent review and evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Sulphonylureas and cancer: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin, diet and breast cancer: an avenue for chemoprevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Structure of mammalian AMPK and its regulation by ADP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

AMPK is a direct adenylate charge-regulated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

AMP-activated protein kinase: nature's energy sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

LKB1 is the upstream kinase in the AMP-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

ATP and MO25α Regulate the Conformational State of the STRADα Pseudokinase and Activation of the LKB1 Tumour Suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Amino acid signaling in TOR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Cell signaling. New mTOR targets Grb attention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The coordinate regulation of the p53 and mTOR pathways in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

TP53 and MTOR crosstalk to regulate cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Autophagy regulation by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Stimulation of autophagy by the p53 target gene Sestrin2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Weak p53 permits senescence during cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Spatial coupling of mTOR and autophagy augments secretory phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Chemical Genomics Identifies the Unfolded Protein Response as a Target for Selective Cancer Cell Killing during Glucose Deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin slows down aging and extends life span of female SHR mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin suppresses intestinal polyp growth in ApcMin/+ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and cancer: new applications for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Is it time to test metformin in breast cancer clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

A phase I study of temsirolimus and metformin in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Biological mechanisms linking obesity and cancer risk: new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and other biguanides in oncology: advancing the research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The association of AMPK with ULK1 regulates autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The AMPK-FoxO3A axis as a target for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Bcl2 family proteins in carcinogenesis and the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Phosphorylation of Beclin 1 by DAP-kinase promotes autophagy by weakening its interactions with Bcl-2 and Bcl-XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

The insulin and insulin-like growth factor receptor family in neoplasia: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.181

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.181

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference